This company engineers modular immunotherapies for cancer treatment by screening millions of protein candidates in living cells. They utilize a high-throughput screening platform coupled with machine learning to rapidly identify and design optimal therapeutic candidates. This integrated approach accelerates the development timeline, delivering best-in-class immunotherapies faster for clinical application.
Funding
$3.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer immunotherapies face challenges in predicting clinical efficacy, often requiring extensive development at a high cost and long wait times for patients. Traditional methods focus primarily on protein binding rather than comprehensively assessing the immune response, limiting the potential for optimal therapy design.
Solution
Coding Bio offers a high-throughput cell discovery platform that leverages machine learning to accelerate the development of effective cancer immunotherapies. The platform screens millions of modular protein candidates directly in living cells, generating vast libraries and identifying designs that best induce an immune response. By screening at scale, Coding Bio gathers previously inaccessible data to fuel its machine learning platform, enabling the identification of optimal therapy designs that go beyond simple binding. This approach significantly reduces development time and increases the likelihood of clinical success.
Target Audience
Coding Bio's primary customers are pharmaceutical companies and research institutions involved in cancer immunotherapy development.
Features
- High-throughput screening of millions of modular protein candidates in living cells
- Generative modeling using machine learning to analyze protein structures and identify patterns impacting therapy quality
- Iterative design process to maximize therapy performance based on machine learning insights
- Integration of data from different disease states to improve understanding of the immune system
- Rapid engineering of best-in-class therapies in a matter of months